Edmond de Rothschild sells Glycovaxyn to GSK
Edmond de Rothschild Investment Partners’ BioDiscovery 3 portfolio company, GlycoVaxyn has been acquired by GlaxoSmithKline (GSK) in an all-cash transaction valuing the company at approximately USD212 million. GlycoVaxyn, founded in 2004, is a spin out of the Swiss Polytechnic Institute of Zürich. It has developed a biological conjugation platform which

